Cellectis S.A.

ALCLS

FR0010425595

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:55:00 10/04/2026 BST			5-day change	1st Jan Change
3.188 ^EUR	+5.01%		+2.67%	-24.00%

04-10	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	MT
04-09	European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	MT

European Equities Traded in the US as American Depositary Receipts Advance Wednesday

Published on 06/04/2025 at 04:19 pm BST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Cellectis S.A.

04-10	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	MT
04-09	European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	MT
04-07	European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading	MT
04-06	European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading	MT
04-01	European Equities Traded in the US as American Depositary Receipts Rising Sharply in Wednesday Trading	MT
03-31	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
03-30	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
03-26	European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	MT
03-20	Cellectis S.A., Q4 2025 Earnings Call, Mar 20, 2026
03-20	European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading; Drop Over 2% for Week	MT
03-20	Cellectis S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-19	HDF, Valbiotis, Cellectis... stocks to watch tomorrow in Paris
03-18	European Equities Traded in US as ADRs Fall in Wednesday Trading	MT
03-13	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
03-12	European Equities Traded in US as ADRs Slump in Thursday Trading	MT

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR T cells for the treatment of cancer patients, and a platform for for the development of gene therapies in other therapeutic indications. Thanks to its fully in-house production capabilities, Cellectis S.A. is one of the few genome-editing companies to control the cell and gene therapy value chain from end to end.

Employees

227

Sector

Biotechnology & Medical Research

More about the company